CLOSE

Case study

Entering the Chinese market can be complex. This is how we helped Regenacy Pharmaceuticals with its expansion.

18 February 2021

The client

Regenacy Pharmaceuticals is a leading US biotech company, developing cutting edge, disease-modifying treatment for peripheral neuropathies – damaged nerve endings, resulting from a variety of medical conditions.

Having been founded in 2016, Regenacy Pharmaceuticals has successfully developed first-in-class potential treatments, and is moving on to the clinic trialing stage of drug development.

In order to support further research and clinical trials, Regenacy Pharmaceuticals will engage in a joint-venture partnership with strategic mainland Chinese partners.

Their challenge

Offering a number of structuring advantages, the most common route to market entry in China for foreign firms is via a Hong Kong holding company.

Unfamiliar with the local requirements to incorporate and maintain a legal entity in Hong Kong, Regenacy Pharmaceuticals sought a market leading services provider, with a deep expertise in end-to-end corporate services.

Our solution

Intertrust Group was recommended to Regenacy by their legal adviser, thanks to our long history of supporting US and European companies to enter the mainland Chinese market, and our expertise in establishing and maintaining Hong Kong investment vehicles.

Having successfully incorporated the Hong Kong company, Intertrust Group is also providing end-to-end corporate services to ensure that all of the local statutory obligations are satisfied to a high standard. Annual services include company secretary, registered office, accounting, audit liaison and tax compliance.

In addition, our team has a deep understanding of gathering the supporting documents required to register a WFOE (‘wholly foreign owned enterprise’) in mainland China. With Regenacy Pharmaceuticals in an exciting stage of their growth, we look forward to continuing to support their future expansion and success.